Latest Insider Transactions at Repare Therapeutics Inc. (RPTX)
This section provides a real-time view of insider transactions for Repare Therapeutics Inc. (RPTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Repare Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Repare Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2024
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
789
-1.73%
|
$3,156
$4.61 P/Share
|
|
Apr 01
2024
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
2,491
-2.26%
|
$9,964
$4.63 P/Share
|
|
Apr 01
2024
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
300
-0.13%
|
$1,200
$4.66 P/Share
|
|
Apr 01
2024
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
410
-0.57%
|
$1,640
$4.66 P/Share
|
|
Mar 28
2024
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
825
-1.78%
|
$3,300
$4.62 P/Share
|
|
Mar 28
2024
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
2,650
-2.35%
|
$10,600
$4.62 P/Share
|
|
Mar 28
2024
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
500
-0.22%
|
$2,000
$4.64 P/Share
|
|
Mar 28
2024
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
450
-0.62%
|
$1,800
$4.64 P/Share
|
|
Mar 27
2024
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
2,650
-3.06%
|
$10,600
$4.63 P/Share
|
|
Mar 27
2024
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
500
-0.21%
|
$2,000
$4.62 P/Share
|
|
Mar 27
2024
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
450
-0.61%
|
$1,800
$4.62 P/Share
|
|
Mar 27
2024
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
825
-1.92%
|
$3,300
$4.62 P/Share
|
|
Mar 26
2024
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
2,650
-2.97%
|
$10,600
$4.64 P/Share
|
|
Mar 26
2024
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
500
-0.21%
|
$2,000
$4.6 P/Share
|
|
Mar 26
2024
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
450
-0.61%
|
$1,800
$4.61 P/Share
|
|
Mar 26
2024
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
825
-1.88%
|
$3,300
$4.6 P/Share
|
|
Mar 25
2024
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
SELL
Open market or private sale
|
Indirect |
2,650
-2.89%
|
$10,600
$4.79 P/Share
|
|
Mar 25
2024
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
500
-0.21%
|
$2,000
$4.78 P/Share
|
|
Mar 25
2024
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
450
-0.61%
|
$1,800
$4.78 P/Share
|
|
Mar 25
2024
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
825
-1.85%
|
$3,300
$4.79 P/Share
|
|
Mar 01
2024
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+23.86%
|
-
|
|
Mar 01
2024
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+24.29%
|
-
|
|
Mar 01
2024
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+15.89%
|
-
|
|
Mar 01
2024
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+5.65%
|
-
|
|
Dec 11
2023
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
43,746
+9.51%
|
$87,492
$2.24 P/Share
|
|
Nov 16
2023
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
295,745
+2.84%
|
$1,478,725
$5.38 P/Share
|
|
Nov 15
2023
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
931,556
+8.5%
|
$4,657,780
$5.0 P/Share
|
|
Nov 02
2023
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
783,709
+9.66%
|
$2,351,127
$3.6 P/Share
|
|
Jun 08
2023
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private sale
|
Direct |
2,869
+4.55%
|
$34,428
$12.02 P/Share
|
|
Jun 07
2023
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
6,404
-9.23%
|
$76,848
$12.03 P/Share
|
|
Jun 06
2023
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,200
-1.7%
|
$14,400
$12.04 P/Share
|
|
Jan 30
2023
|
Lloyd Mitchell Segal PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
78,550
+48.12%
|
-
|
|
Jan 30
2023
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
26,450
+13.07%
|
-
|
|
Jan 30
2023
|
Michael Zinda EVP, CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
24,550
+25.8%
|
-
|
|
Jan 30
2023
|
Steve Forte EVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
24,530
+44.42%
|
-
|
|
Dec 29
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Direct |
4,254
+8.01%
|
-
|
|
Dec 29
2022
|
Davis Jerel Director |
SELL
Other acquisition or disposition
|
Indirect |
397,888
-55.84%
|
-
|
|
Dec 29
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Indirect |
70,678
+26.47%
|
-
|
|
Dec 20
2022
|
Maria Koehler EVP, CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
48,507
+12.26%
|
$97,014
$2.24 P/Share
|
|
Dec 09
2022
|
Davis Jerel Director |
SELL
Open market or private sale
|
Indirect |
250,000
-10.66%
|
$4,000,000
$16.0 P/Share
|
|
Jun 13
2022
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
149,161
+1.72%
|
$1,789,932
$12.73 P/Share
|
|
Jun 06
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Direct |
9,101
+19.56%
|
-
|
|
Jun 06
2022
|
Davis Jerel Director |
SELL
Other acquisition or disposition
|
Indirect |
851,202
-61.29%
|
-
|
|
Jun 06
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Indirect |
151,202
+26.47%
|
-
|
|
Jun 06
2022
|
Versant Ventures V, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
710,099
-53.55%
|
-
|
|
Jun 06
2022
|
Versant Ventures V, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
10,099
+50.0%
|
-
|
|
Jun 06
2022
|
Versant Ventures V, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
141,103
-100.0%
|
-
|
|
Jun 06
2022
|
Versant Ventures V, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
141,103
+18.62%
|
-
|
|
Jun 06
2022
|
Versant Vantage I, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
851,202
-61.29%
|
-
|
|
Jun 06
2022
|
Versant Vantage I, L.P. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
151,202
+26.47%
|
-
|